[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.

Progressive dedifferentiation of thyroid cancer cells leads to a loss of iodine-concentrating ability, with resultant false negative, whole body radioactive iodine scans in approximately 20% of all differentiated metastatic thyroid cancer lesions. We tested the hypothesis that all metastatic thyroid cancer lesions that did not concentrate iodine, but did produce thyroglobulin (Tg), could be localized by [18F]2-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET). We performed FDG-PET on 37 patients with differentiated thyroid cancer after surgery and radioiodine ablation who had negative diagnostic 131I whole body scans during routine follow-up. Serum Tg, Tg autoantibodies, neck ultrasounds, and other clinically indicated imaging procedures were performed to detect residual disease. In those with elevated Tg levels, FDG-PET localized occult disease in 71%, was false positive in one, and was false negative in five patients. The majority of false negative FDG-PET occurred in patients with minimal cervical adenopathy. Surgical resections, biopsies, 131 therapy, and differentiation therapy were performed based on the PET results. The FDG-PET result changed the clinical management in 19 of the 37 patients. In patients with elevated Tg levels, FDG-PET had a positive predictive value of 92%. In patients with low Tg levels, FDG-PET had a negative predictive value of 93%. No FDG-PET scans were positive in stage I patients; however, they were always positive in stage IV patients with elevated Tg levels. An elevated TSH level (i.e. hypothyroidism) did not increase the ability to detect lesions. FDG-PET is able to localize residual thyroid cancer lesions in patients who have negative diagnostic 131I whole body scans and elevated Tg levels, although it was not sensitive enough to detect minimal residual disease in cervical nodes.

[1]  J. Ruhlmann,et al.  Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. , 1997, Thyroid : official journal of the American Thyroid Association.

[2]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  A. Bockisch,et al.  Technetium-99m-furifosmin in the follow-up of differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  N. Jaffe,et al.  Intraarterial cis‐platinum for patients with inoperable skeletal tumors , 1981, Cancer.

[5]  O. Schober,et al.  Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.

[6]  U. Feine Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. , 1998, European journal of endocrinology.

[7]  C. Spencer,et al.  Current status and performance goals for serum thyrotropin (TSH) assays. , 1996, Clinical chemistry.

[8]  I. Mcdougall 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? , 1997, Thyroid : official journal of the American Thyroid Association.

[9]  L. Adler,et al.  Positron emission tomography of thyroid masses. , 1993, Thyroid : official journal of the American Thyroid Association.

[10]  R. Wahl,et al.  Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. , 1993, The Journal of clinical endocrinology and metabolism.

[11]  A. Pinchera,et al.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  T. Endo,et al.  The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin. , 1992, Endocrinology.

[13]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[15]  E. Baudin,et al.  Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. , 1998, European journal of endocrinology.

[16]  M. Clausen,et al.  Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer , 1998, Langenbeck's Archives of Surgery.

[17]  H. Joensuu,et al.  Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  H. Macapinlac,et al.  Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. , 1998, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[19]  J. Miller,et al.  Metastatic Papillary Thyroid Carcinoma with Normal Serum Thyroglobulin Level , 1988, Clinical nuclear medicine.

[20]  M. Dietlein,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[21]  J. Høie,et al.  Distant metastases in papillary thyroid cancer. A review of 91 patients , 1988, Cancer.

[22]  J. Hanke,et al.  [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.

[23]  N. Sadato,et al.  Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. , 1998, Journal of Nuclear Medicine.

[24]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[25]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[26]  T. Fukumura,et al.  Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.